Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease

Van de Veire, Sara and Stalmans, Ingeborg and Heindryckx, Femke and Oura, Hajimu and Tijeras-Raballand, Annemilaï and Schmidt, Thomas and Loges, Sonja and Albrecht, Imke and Jonckx, Bart and Vinckier, Stefan and Van Steenkiste, Christophe and Tugues, Sònia and Rolny, Charlotte and De Mol, Maria and Dettori, Daniela and Hainaud, Patricia and Coenegrachts, Lieve and Contreres, Jean-Olivier and Van Bergen, Tine and Cuervo, Henar and Xiao, Wei-Hong and Le Henaff, Carole and Buysschaert, Ian and Kharabi Masouleh, Behzad and Geerts, Anja and Schomber, Tibor and Bonnin, Philippe and Lambert, Vincent and Haustraete, Jurgen and Zacchigna, Serena and Rakic, Jean-Marie and Jiménez, Wladimiro and Noël, Agnes and Giacca, Mauro and Colle, Isabelle and Foidart, Jean-Michel and Tobelem, Gerard and Morales-Ruiz, Manuel and Vilar, José and Maxwell, Patrick and Vinores, Stanley A. and Carmeliet, Geert and Dewerchin, Mieke and Claesson-Welsh, Lena and Dupuy, Evelyne and Van Vlierberghe, Hans and Christofori, Gerhard and Mazzone, Massimiliano and Detmar, Michael and Collen, Désiré and Carmeliet, Peter. (2010) Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell, Vol. 141, H. 1. pp. 178-190.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6006805

Downloads: Statistics Overview

Abstract

Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.

Faculties and Departments:	03 Faculty of Medicine > Departement Biomedizin > Former Units at DBM > Tumor Biology (Christofori)
UniBasel Contributors:	Christofori, Gerhard M.
Item Type:	Article, refereed
Article Subtype:	Research Article
Publisher:	Cell Press
ISSN:	0092-8674
Note:	Publication type according to Uni Basel Research Database: Journal article
Related URLs:	Document
Identification Number:	pmid: 20371353
Last Modified:	07 Dec 2012 13:03
Deposited On:	07 Dec 2012 13:00

Repository Staff Only: item control page